These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 30801965)
21. Design and synthesis of potent Gram-negative specific LpxC inhibitors. Mansoor UF; Vitharana D; Reddy PA; Daubaras DL; McNicholas P; Orth P; Black T; Siddiqui MA Bioorg Med Chem Lett; 2011 Feb; 21(4):1155-61. PubMed ID: 21273067 [TBL] [Abstract][Full Text] [Related]
22. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs. Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290 [TBL] [Abstract][Full Text] [Related]
24. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria. Liu F; Ma S Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357 [TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Evaluation of Vanillin Hydroxamic Acid Derivatives as Novel Peptide Deformylase Inhibitors. Gao J; Qiu S; Liang L; Hao Z; Zhou Q; Wang F; Mou J; Lin Q Curr Comput Aided Drug Des; 2018; 14(1):95-101. PubMed ID: 28606047 [TBL] [Abstract][Full Text] [Related]
26. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors. Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072 [TBL] [Abstract][Full Text] [Related]
28. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532. Ushiyama F; Takashima H; Matsuda Y; Ogata Y; Sasamoto N; Kurimoto-Tsuruta R; Ueki K; Tanaka-Yamamoto N; Endo M; Mima M; Fujita K; Takata I; Tsuji S; Yamashita H; Okumura H; Otake K; Sugiyama H Bioorg Med Chem; 2021 Jan; 30():115964. PubMed ID: 33385955 [TBL] [Abstract][Full Text] [Related]
29. Peptide deformylase inhibitors with non-peptide scaffold: synthesis and structure-activity relationships. Lee SK; Choi KH; Lee SJ; Lee JS; Park JY; Kim BM; Lee BJ Bioorg Med Chem Lett; 2011 Jan; 21(1):133-6. PubMed ID: 21146987 [TBL] [Abstract][Full Text] [Related]
30. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches. Sharma A; Kumar V; Pratap S; Kumar P Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978 [TBL] [Abstract][Full Text] [Related]
31. Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC. Warmus JS; Quinn CL; Taylor C; Murphy ST; Johnson TA; Limberakis C; Ortwine D; Bronstein J; Pagano P; Knafels JD; Lightle S; Mochalkin I; Brideau R; Podoll T Bioorg Med Chem Lett; 2012 Apr; 22(7):2536-43. PubMed ID: 22401863 [TBL] [Abstract][Full Text] [Related]